Lexicon Pharmaceuticals Inc [LXRX] stock is trading at $0.87, down -3.13%. An important factor to consider is whether the stock is rising or falling in short-term value. The LXRX shares have gain 6.32% over the last week, with a monthly amount glided 32.02%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] stock has seen the most recent analyst activity on March 05, 2025, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $1 from $2. Previously, H.C. Wainwright started tracking the stock with Buy rating on June 17, 2024, and set its price target to $10. On April 30, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $5 on the stock. Jefferies started tracking the stock assigning a Hold rating and suggested a price target of $3 on March 07, 2023. Piper Sandler initiated its recommendation with a Overweight and recommended $10 as its price target on August 12, 2022. JP Morgan upgraded its rating to Neutral for this stock on January 29, 2021, but kept the price target unchanged to $7. In a note dated January 29, 2021, Wedbush downgraded an Neutral rating on this stock and boosted its target price from $2 to $8.
Lexicon Pharmaceuticals Inc [LXRX] stock has fluctuated between $0.28 and $2.45 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] shares were valued at $0.87 at the most recent close of the market. An investor can expect a potential return of 589.66% based on the average LXRX price forecast.
Analyzing the LXRX fundamentals
Lexicon Pharmaceuticals Inc [NASDAQ:LXRX] reported sales of 31.21M for the trailing twelve months, which represents a growth of 11.68%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -5.69%, Pretax Profit Margin comes in at -5.68%, and Net Profit Margin reading is -5.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -1.03 and Total Capital is -0.95. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8367 points at the first support level, and at 0.8007 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9084, and for the 2nd resistance point, it is at 0.9441.
Ratios To Look Out For
For context, Lexicon Pharmaceuticals Inc’s Current Ratio is 2.22. On the other hand, the Quick Ratio is 2.22, and the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 10.16, the price to book ratio is 2.58.
Transactions by insiders
Recent insider trading involved COATS LONNEL, Former Affiliate, that happened on Aug 15 ’24 when 0.3 million shares were purchased.
